Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Primary Prophylaxis with Eflapegrastim During FOLFIRINOX Chemotherapy in Locally Advanced or Metastatic Pancreatic Cancer
KCT0009965Phase 2Not yet recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of esketamine in Pancreatic neoplasia, sponsored by Hanmi Pharmaceutical. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
Pancreatic neoplasia
Beyond the preview
Go deeper on KCT0009965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009965.